---
title: "BioKangtai: Quadrivalent influenza virus split vaccine (for the population aged 6-35 months) has initiated Phase I clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263999798.md"
description: "BioKangtai: Quadrivalent influenza virus split vaccine (6-35 months age group) has initiated Phase I clinical trial"
datetime: "2025-11-03T11:14:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263999798.md)
  - [en](https://longbridge.com/en/news/263999798.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263999798.md)
generator: "portal-rs"
---

# BioKangtai: Quadrivalent influenza virus split vaccine (for the population aged 6-35 months) has initiated Phase I clinical trials

According to the Zhitong Finance APP, BioKangtai (300601.SZ) announced that the Phase I clinical trial preparation for its quadrivalent influenza virus split vaccine (for the 6-35 month age group) has been completed, and the Phase I clinical trial has commenced, with the first subject successfully enrolled recently. This quadrivalent influenza virus split vaccine, which has entered Phase I clinical trials, is suitable for the 6-35 month age group and can stimulate the body to produce immunity against influenza viruses, used for the prevention of influenza caused by vaccine-related strains

### Related Stocks

- [300601.CN](https://longbridge.com/en/quote/300601.CN.md)

## Related News & Research

- [Health Rounds: Psychedelic drug shows promise for preventing chemotherapy-induced nerve damage](https://longbridge.com/en/news/297960476.md)
- [Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk](https://longbridge.com/en/news/297887371.md)
- [09:47 ETBD&J Named to the Prestigious 2026 Chambers and Partners Spotlight Guide for California](https://longbridge.com/en/news/297662965.md)
- [Cleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood Test](https://longbridge.com/en/news/297848437.md)
- [Generational Group Advises Cantor BioConnect in its Sale to Prairie Capital](https://longbridge.com/en/news/297685099.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**